Vertex Pharmaceuticals Report Encouraging Preliminary Data From Phase II Clinical Study With HIV Protease Inhibitor 141W94

October 13, 1997

Cambridge, MA, October 13, 1997 -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced for the first time preliminary 12 week data from an ongoing Phase II study of 141W94 (VX-478), an HIV protease inhibitor currently in Phase III clinical trials. The data, presented at the 6th European Conference on Clinical Aspects and Treatment of HIV-infection in Hamburg, Germany, showed that 141W94 in combination with RetrovirR (AZT) and EpivirR (3TC) was generally well-tolerated and produced potent antiviral activity. In the triple combination study (141W94, AZT, 3TC), approximately 70% of patients had undetectable viral load at 12 weeks.

"This study is the first of a series of data to be presented on 141W94, and support the favorable tolerability and antiviral profile of the compound," commented Dr. Vicki L. Sato, Senior Vice President of Research and Development and Chief Scientific Officer of Vertex. "Additional 141W94 data from a number of treatment regimens is expected in the coming months."

"In the context of current therapy, the Phase II triple combination study shows that 141W94 displayed potent antiviral activity at all three doses tested in combination with AZT and 3TC," commented Mike Rogers, Ph.D., Assistant Director, Antiviral Clinical Research at Glaxo Wellcome. "This study is part of an extensive international clinical program to evaluate 141W94 in a variety of drug regimens and patient populations for the management of HIV infection."

At the conference, Dr. Stephane de Wit of Saint-Pierre University Hospital in Brussels, Belgium, reported results from the "Vanguard" study, a pilot efficacy trial of three doses (900 mg, 1050 mg and 1200 mg, twice daily) of 141W94 in combination with RetrovirR (AZT) and EpivirR (3TC). At 12 weeks, patients taking 141W94 at the highest dose, 1200mg twice daily, plus RetrovirR (AZT) and EpivirR (3TC) had a median 2.65 log reduction in viral load (greater than 99.8%) from baseline as compared to a 1.33 log reduction for the control arm, RetrovirR and EpivirR. At 12 weeks, approximately 70 percent of patients across all 141W94 dose groups experienced drops in HIV viral load to below the limits of detection (400 copies HIV RNA/ml) for the assay used. The combination was generally well-tolerated with diarrhea, headache, nausea and rash being the most commonly reported adverse events for patients treated with these three drugs.

Since early 1997, Glaxo Wellcome has been conducting extensive pivotal Phase III clinical trials of 141W94. Three pivotal Phase III clinical trials are ongoing to assess the tolerability and antiviral activity of 141W94 in combination therapy in HIV-positive adults and children. The Phase III clinical trial initiated earlier this year in adults is fully enrolled and a third Phase III clinical trial begun last month comparing 141W94 with indinavir is expected to enroll patients rapidly. Data generated from 16 weeks of treatment in these studies is intended to support filing of market approval of 141W94. To date approximately 500 patients have participated in 141W94 clinical studies. More than 125 clinical trial sites in the United States, Canada, Europe and Australia and more than 1000 patients are expected to participate in the ongoing Phase II and pivotal Phase III clinical evaluation of 141W94.

141W94, a second generation HIV protease inhibitor, was designed at Vertex Pharmaceuticals and is being developed by Glaxo Wellcome worldwide, outside of the Far East, and Kissei Pharmaceutical Co., Ltd. (Matsumoto-City, Japan) in the Far East.

Glaxo Wellcome is a world leader in developing therapies for the treatment of HIV and AIDS. RetrovirR was the first antiviral medicine developed for use in adults and children with HIV infection. Retrovir was introduced in 1987 and is now available in over 100 countries. EpivirR has been cleared for use in over 25 countries including the US and the European Union. Epivir has also been approved as 3TC in Canada, Australia, South Africa, Switzerland, Uruguay, New Zealand, Mexico, Colombia and Argentina. In addition, Glaxo Wellcome discovered, developed and markets several products for the treatment of HIV-related opportunistic infections.

Vertex Pharmaceuticals Incorporated is engaged in the discovery, development and commercialization of novel, small molecule pharmaceuticals for the treatment of diseases for which there are currently limited or no effective treatments. The Company is a leader in the use of structure-based drug design, an approach to drug discovery that integrates advanced biology, biophysics and chemistry. The Company is concentrating on the discovery and development of drugs for the treatment of viral diseases, multidrug resistance in cancer, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases.

Epivir and 3TC (lamivudine) and Retrovir and AZT (zidovudine) are trademarks of the Glaxo Wellcome Group of Companies.

Additional Glaxo contact: Doug Stokke, Manager, Product Communications (919) 483-2311

Additional Vertex contact: Justine Schultz, Corporate Communications Specialist, (617) 577-6000

Vertex's press releases are also available by fax-on-demand at (800) 758-5804 -- Code: 938395

There can be no assurance that the planned clinical trials will continue, that initial clinical trial results will be predictive of any future results, that drugs under development by the Company or any of its partners will receive marketing approval from the U.S. Food and Drug Administration or other authorities, or that drugs, if any, which receive such approval will be marketed successfully. Investors are also directed to consider other risks and uncertainties discussed in documents filed by the company with the Securities and Exchange Commission.
-end-
#

Vertex Pharmaceuticals

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.